PROTEOMIC STUDIES IN ATHEROSCLEROSIS
https://doi.org/10.15372/ATER20180309
Abstract
The review is devoted to the analysis of literature data related to the role of proteomic technologies in the study of atherosclerotic cardiovascular diseases. The results of research on the search for new proteomic potential biomarkers of coronary atherosclerosis, coronaryc heart disease, acute coronary syndrome, myocardial infarction, carotid atherosclerosis, and proteomic markers of unstable atherosclerotic plaque are presented. It is discussed that proteomic analysis is a promising developing field of research.
About the Authors
Yu. I. Ragino
Institute of Internal and Preventive Medicine - Branch of Federal Research Institute of Cytology and genetics of SB RAS
Russian Federation
Russian Federation
E. M. Stakhneva
Institute of Internal and Preventive Medicine - Branch of Federal Research Institute of Cytology and genetics of SB RAS
Russian Federation
Russian Federation
References
1. Арчаков А.И. Биоинформатика, геномика и протеомика - науки о жизни XXI столетия // Вопр. мед. химии. 2000. № 1. С. 13-18.
2. http://www.plasmaproteomedatabase.org
3. Addona T.A., Abbatiello S.E., Schilling B. et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma // Nat. Biotechnol. 2009. Vol. 27, N 7. P. 633-641.
4. Xia J.Q., Sedransk N., Feng X. Variance component analysis of a multi-site study for the reproducibility of multiple reaction monitoring measurements of peptides in human plasma // PLoS One. 2011. Vol. 6, N 1. P. e14590.
5. Ganz P., Heidecker B., Hveem K. et al. Development and validation of a protein based risk score for cardiovascular outcomes among patients with stable coronary heart disease // JAMA. 2016. Vol. 315, N 23. P. 2532-2541.
6. Wang G., Mathew A.V., Yu H. et al. Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease // PLoS One. 2018. Vol. 13, N 3. P. e0193782.
7. V A., Nayar P.G., Murugesan R. et al. A systems biology and proteomics-based approach identifies SRC and VEGFA as biomarkers in risk factor mediated coronary heart disease // Mol. Biosyst. 2016. Vol. 12, N 8. P. 2594-2604.
8. Krishnan S., Huang J., Lee H. et al. Combined High-Density Lipoprotein Proteomic and Glycomic Profiles in Patients at Risk for Coronary Artery Disease // J. Proteome Res. 2015. Vol. 14, N 12. P. 5109-5118.
9. Cao D.J., Hill J.A. Copper Futures. Ceruloplasmin and Heart Failure // Circ. Res. 2014. Vol. 114. P. 1678-1680.
10. Cabassi A., Binno S.M., Tedeschi S. Low Serum ferroxidase activity is associated with mortality in heart failure and related to both peroxynitrite-induced cysteine oxidation and tyrosine nitration of ceruloplasmin // Circ. Res. 2014. Vol. 114. P. 1723-1732.
11. Lepedda A.J., Lobina O., Rocchiccioli S. et al. Identification of differentially expressed plasma proteins in atherosclerotic patients with type 2 diabetes // J. Diabetes Compl. 2016. Vol. 30, N 5. P. 880-886.
12. Shan L., Pang L., Zhang R. et al. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide // Biochem. Biophys. Res. Commun. 2008. Vol. 375, N 1. P. 69-73.
13. Ljungberg J., Janiec M., Bergdahl I.A. et al. Proteomic biomarkers for incident aortic stenosis requiring valvular replacement // Circulation. 2018. pii: CIRCULATIONAHA. 117.030414. DOI: 10.1161/CIRCULATIONAHA. 117.030414.
14. Langley S.R., Willeit K., Didangelos A. et al. Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques // J. Clin. Invest. 2017. Vol. 127, N 4. P. 1546-1560.
15. Lind L., Ärnlöv J., Lindahl B. et al. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis // Atherosclerosis. 2015. Vol. 242, N 1. P. 205-210.
16. Patzelt J., Verschoor A., Langer H.F. Platelets and the complement cascade in atherosclerosis // Front. Physiol. 2015. Vol. 6. P. 49-54.
17. Stakhneva E.M., Meshcheryakova I.A., Demidov E.A. et al. Proteomic study of blood serum in coronary atherosclerosis // Bull. Exp. Biol. Med. 2017. Vol. 162, N 3. P. 343-345.
18. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques // Am. J. Pathol. 2001. Vol. 158, N 3. P. 1039-1051.
19. De Hoog V.C., Timmers L., Schoneveld A.H. et al. Serum extracellular vesicle protein levels are associated with acute coronary syndrome // Eur. Heart J. Acute Cardiovasc. Care. 2013. Vol. 2, N 1. P. 53-60.
20. Yin X., Subramanian S., Hwang S.J. et al. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative // Arterioscler. Thromb. Vasc. Biol. 2014. Vol. 34, N 4. P. 939-945.
21. Haas B., Serchi T., Wagner D.R. et al. Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker // J. Proteomics. 2011. Vol. 75, N. 1. P. 229-236.
22. Raizada A., Bhandari S., Khan M.A. et al. Brain type natriuretic peptide (BNP)-A marker of new millennium in diagnosis of congestive heart failure // Indian J. Clin. Biochem. 2007. Vol. 22, N 1. P. 4-9.
23. Xu X., Li Z., Gao W. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside // Biomarkers. 2011. Vol. 16, N 6. P. 466-475.
24. Schiopu A., Cotoi O.S. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease // Mediators Inflamm. 2013. Vol. 828, N 3. P. 54-61.
25. Navas-Carrillo D., Marнn F., Valdés M., Orenes-Piсero E. Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles // Crit. Rev. Clin. Lab. Sci. 2017. Vol. 54. N 1. P. 49-58.
26. Basak T., Varshney S., Akhtar S., Sengupta S. Understanding different facets of cardiovascular diseases based on model systems to human studies: a proteomic and metabolomic perspective // J. Proteomics. 2015. Vol. 127 (Pt A). P. 50-60.
27. Sentman M.L., Granström M., Jakobson H. et al. Phenotypes of mice lacking extracellular superoxide dismutase and copper- and zinc-containing superoxide dismutase// J. Biol. Chem. 2006. Vol. 281, N 11. P. 6904-6909.
28. Rao N.M., Capri J., Cohn W. et al. Peptide composition of stroke causing emboli correlate with serum markers of atherosclerosis and inflammation // Front. Neurol. 2017. Vol. 8. P. 427-431.
29. Lepedda A.J., Nieddu G., Zinellu E. et al. Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker // Oxidat. Med. and Cell. Long. 2013. Vol. 38, N 5. P. 214-225.
30. Herrington D.M., Mao C., Parker S.J. et al. Proteomic Architecture of Human Coronary and Aortic Atherosclerosis // Circulation. 2018. Vol. 137, N 25. P. 2741-2756.
31. Han Y., Zhao S., Gong Y. et al. Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation // Oncotarget. 2016. Vol. 7, N 2. P. 1854-1862.
32. Lepedda A.J., Cigliano A., Cherchi G.M. et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries // Atherosclerosis. 2009. Vol. 203, N 1. P. 112-118.
33. Olson F.J., Sihlbom C., Davidsson P. et al. Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques // Biochem. Biophys. Res. Commun. 2010. Vol. 401, N 4. P. 574-580.
34. Rocchiccioli S., Pelosi G., Rosini S. et al. Secreted proteins from carotid endarterectomy: an untargeted approach to disclose molecular clues of plaque progression // J. Transl. Med. 2013. Vol. 11. P. 260-267.
Review
For citations:
Ragino Yu.I., Stakhneva E.M. PROTEOMIC STUDIES IN ATHEROSCLEROSIS. Ateroscleroz. 2018;14(3):56-63. (In Russ.) https://doi.org/10.15372/ATER20180309
Views:
280
Email this article 